An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice

Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips

Journal article

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice

Kathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, Paul Waring, Ivan Ivetac, Anjali Tikoo, Mirette Saad, Lauren Hare, Vincent Roh, Theo Mantamadiotis, Karen E Sheppard, Georgina L Ryland, Ian G Campbell, Kylie L Gorringe, James G Christensen, Carleen Cullinane, Rodney J Hicks, Richard B Pearson, Ricky W Johnstone, Grant A McArthur Show all

Journal of Clinical Investigation | AMER SOC CLINICAL INVESTIGATION INC | Published : 2012

DOI: 10.1172/JCI59309

University of Melbourne Researchers

Grant McArthur Author Melbourne Medical School

Paul Waring Author Clinical Pathology

Kylie Gorringe Author The Sir Peter MacCallum Department of Oncology

Richard Pearson Author The Sir Peter MacCallum Department of Oncology

Wayne Phillips Author The Sir Peter MacCallum Department of Oncology

Related Projects (2)

Characterisation Of A Pik3ca Mutation In Breast And Ovarian Cancer

PIK3CA mutations are frequently found in breast and ovarian cancers but how they cause cancer is not clear. We will exploit a unique mouse m..

New Therapies For Myc-Associated Cancers

This proposal will evaluate a new strategy for treating cancers associated with the cancer causing gene MYC. Globally there are more than 1 ..

Grants

Awarded by NHMRC

Awarded by Association of International Cancer Research

Funding Acknowledgements

We thank Kerry Ardley for animal experiments and the Peter Mac core histology and pathology facilities. This work was supported by the NHMRC (grant no. 628620 to W.A. Phillips and no. 566876 to G.A. McArthur and R.B. Pearson); the Association of International Cancer Research (no. 10-0052 to W.A. Phillips); Pfizer (grant to G.A. McArthur and R.J. Hicks); the Cancer Council Victoria and the Victorian Cancer Agency (grants to R.W. Johnstone); and the Victorian Breast Cancer Research Consortium, Australia (to I.G. Campbell and K.L. Gorringe). Researchers were funded by a Sir Edward Weary Dunlop Fellowship, Cancer Council of Victoria (to G.A. McArthur); research fellowships from the NHMRC (to R.B. Pearson and R.W. Johnstone); Cure Cancer Australia Foundation and Cancer Australia (to I. Ivetac); the Egyptian government and NHMRC (to M. Saad); Australian Postgraduate Research Awards (to L. Hare and G.L. Ryland); and the Swiss National Science Foundation (to V. Roh).